L3VLUP
ProSign in

RPRX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RPRXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RPRX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterRPRXJNJ
Q3 20207 holders, $1.6bn30 holders, $26.2bn
Q4 20205 holders, $1.9bn32 holders, $26.6bn
Q1 20215 holders, $1.5bn31 holders, $25.3bn
Q2 20218 holders, $1.5bn37 holders, $25.6bn
Q3 20216 holders, $1.4bn40 holders, $24.1bn
Q4 20218 holders, $1.8bn33 holders, $25.2bn
Q1 20228 holders, $1.8bn35 holders, $28.2bn
Q2 202210 holders, $3.2bn33 holders, $26.9bn
Q3 202211 holders, $3.4bn36 holders, $25.4bn
Q4 202217 holders, $3.4bn35 holders, $27.6bn
Q1 202314 holders, $2.9bn42 holders, $24.5bn
Q2 202316 holders, $2.3bn38 holders, $25.0bn
Q3 202314 holders, $1.9bn37 holders, $18.9bn
Q4 202313 holders, $2.1bn31 holders, $19.0bn
Q1 202410 holders, $2.2bn32 holders, $19.7bn
Q2 202412 holders, $1.7bn35 holders, $20.4bn
Q3 202410 holders, $2.0bn28 holders, $22.3bn
Q4 202410 holders, $1.6bn37 holders, $20.4bn
Q1 20259 holders, $2.3bn32 holders, $20.5bn
Q2 20259 holders, $2.4bn31 holders, $18.4bn
Q3 202511 holders, $1.9bn32 holders, $23.7bn
Q4 202510 holders, $2.4bn29 holders, $27.8bn
Q1 202615 holders, $3.1bn34 holders, $35.6bn
Q2 202615 holders, $3.9bn33 holders, $39.1bn
RPRX

Royalty Pharma PLC

Holders
15
Reported value
$3.9bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RPRX (7)

Baillie Gifford & Co, PDT Partners LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Tudor Investment Corp, Two Sigma Investments LP, Winton Group Ltd

Only JNJ (25)

Acadian Asset Management LLC, AllianceBernstein LP, Balyasny Asset Management LLC, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →